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Abstract
Background
Visceral leishmaniasis (VL), one of the neglected tropical diseases, is endemic in the Indian
subcontinent. Ficolins are circulating serum proteins of the lectin complement system and
involved in innate immunity.
Methods
We have estimated ficolin-2 serum levels and analyzed the functional variants of the encod-
ing gene FCN2 in 218 cases of VL and in 225 controls from an endemic region of India.
Results
Elevated levels of serum ficolin-2 were observed in VL cases compared to the controls (ad-
justed P<0.0001). The genetic analysis revealed that the FCN2structural variant +6359
C>T (p.T236M) was associated with VL (OR=2.2, 95% CI=1.23-7.25, P=0.008) and with
high ficolin-2 serum levels. We also found that the FCN2*AAAC haplotype occurred more
frequently among healthy controls when compared to cases (OR=0.59, 95%CI=0.37-0.94,
P=0.023).
Conclusions
Our findings indicate that the FCN2 variant +6359C>T is associated with the occurrence of
VL and that ficolin-2 serum levels are elevated in Leishmania infections.
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Introduction
Visceral leishmaniasis (VL; Kala-Azar), a neglected tropical disease strongly associated with
poverty, claims 400.000 new cases and 40.000 deaths annually [1]. VL leads to a loss of about
2 million disability adjusted life years (DALYs) every year [2]. The vector-borne infection oc-
curs in the four distinct clinical manifestations as cutaneous leishmaniasis, muco-cutaneous
leishmaniasis, VL and post-kala-azar dermal leishmaniasis [3]. VL is the severest form and se-
verely affects visceral organs including the spleen, liver and lymph nodes [4]. Although trans-
mission of VL has been reported in 66 countries, more than 90% of the disease burden are
observed in six countries only, viz. Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil [3].
Among these countries, the Indian sub-continent (India, Nepal and Bangladesh) harbours 67%
of the global VL disease burden [5]. In particular, the Bihar state of India shares 50% of VL and
is considered a “hot spot” of VL [6]. Inadequate vector control practice and disease manage-
ment have been claimed to be responsible for the increased incidence of VL and associated
mortality in India [7].
Leishmania donovani is the causative agent of VL in India. The organism is transmitted to
mammalian hosts by infective bites of the sandfly Phlebotomus argentipes. L. donovani is a uni-
cellular trypanosomatid protozoan parasite with a dimorphic life cycle between the sandfly vec-
tor (extracellular promastigotes) and the human host (intracellular amastigotes) [8]. Both
developmental stages of L. donovani are coated with various secreted and membrane bound
phosphoglycans. During the promastigote stage, abundant lipohosphoglycan (LPG) and gp63
are expressed, which aid immune evasion of the parasite by inhibiting the phagolysosome bio-
genesis in phagocytes [9]. Further, these glycoconjugates facilitate the parasite´s survival in the
hostile macrophage environment [10]. However, LPG and gp36 may also serve as pathogen-as-
sociated molecular patterns (PAMPs) which are recognized by pattern recognition molecules
(PRMs) of the innate system such as complement serum proteins, mannose-binding lectin
(MBL), ficolins (FCN), other soluble C-type lectins and toll-like receptors [11]. Serum comple-
ment activating pattern recognition molecules act in a first-line innate defense against promas-
tigotes inoculated by the sandfly bite. Leishmania parasites have developed various evasion
strategies to avoid the lytic action of the complement system. The parasites use host comple-
ment proteins to escape the immune attack by entering into macrophages [12]. Mannose-
binding lectin (MBL), a circulating serum protein, recognizes the carbohydrate domain of L.
major, L.mexicana, and L. braziliensis. MBL binds to the surface of Leishmania promastigotes
to opsonize the parasites. Upon binding to parasites, MBL initiates the complement cascade
and provides an additional uptake mechanism of parasites by enhancing opsonophagocytosis
and protects them from the immune attack [13,14] and, thus, modulates the clinical outcome
of VL [15].
Ficolins are serum complement lectins that are structurally and functionally analogous to
MBL [16] and, hence, expected to modify the clinical outcome of VL due to their involvement
in innate immunity. Interestingly, a significant association of a distinct FCN2 haplotype with
cutaneous leishmaniasis has been reported from a Syrian population [17]. Ficolins are a group
of complement activating pattern recognition molecules consisting of a collagen-like tail region
and a fibrinogen-like domain (FBG) [18]. Three types of ficolins (Ficolin-1, -2, -3) of similar
structure exist in humans. These types have differential tissue expression patterns and func-
tions [19]. The role of ficolin-2, as an innate immunity component, has been studied in several
infectious diseases including Hepatitis B, schistosomiasis, Chagas disease and others [16,20–
22]. Ficolin-2 recognizes superficial acetylated compounds of invading pathogens by their FBG
domain and initiates the lectin complement cascade [23]. The FCN2 gene localizes to chromo-
some 9q34.3 (OMIM 601624) and hepatic cells predominantly express the corresponding
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protein. The variants in the promoter region of FCN2 gene at positions -986A>G, -602G>A
and -4A>G have been observed to modulate the circulating ficolin-2 concentration in a dose-
dependent manner. The non-synonymous exon-8 variant alleles at positions +6359C>T and
+6424G>T were shown to exhibit differential binding affinities to acetylated compounds when
compared to the wildtype reference alleles [24]. Studies have shown that inter-individual varia-
tion of circulating ficolin-2 concentration are correlated with polymorphisms in the promoter
and exon-8 regions [25].
Although it has been showed that FCN2 gene polymorphisms and haplotypes are associated
with cutaneous leishmaniasis [17], no investigations of ficolins have so far focused on VL.
Moreover, we recently observed that functionalMBL2 polymorphisms and lower MBL levels
confer relative protection against VL (unpublished). As ficolin-2 shares similarities both in
structure and function with MBL [26], we aimed to explore the role of potentially important
FCN2 gene variants and circulating ficolin-2 levels in VL in our Indian study group. Three pro-
moter SNPs (-986A>G, -602G>A and -4A>G) and two structural SNPs in exon 8 (+-
6359C>T and +6424G>T) were genotyped and studied.
Materials and Methods
Ethics statement
Informed written consent was obtained either from the participating individual or from the pa-
rents/guardians if an individual was less than 18 years old. The study was approved by the In-
stitutional Ethical Committee (IEC) of the CSIR-Centre for Cellular and Molecular Biology
(CCMB), Hyderabad, India. Permission was also sought for and obtained from district
government hospitals.
Study design and sample collection
This is a case-control study matched for ethnicity, sex and geographical location. All cases and
controls were recruited through multiple field visits from villages located within a radius of
~120 km from the city of Muzaffarpur in the Bihar state of India. Previous epidemiological
studies of VL have indicated that the Bihar state is a hot spot for VL with an average annual in-
cidence of 2.49/1000 individuals [6]. The sample size was calculated prior to recruitment using
the Open Epi platform (http://www.openepi.com/) based on the incidence rate and the risk of
VL in the study area. A total of 443 unrelated subjects (218 cases and 225 healthy controls)
were recruited. The mean age of VL cases was 28.7±16.7 and 35.3±16.2 in healthy controls
(P = 0.001). No significant difference in the male/female ratio was observed in cases (125:95)
and controls (122:93). The cases were determined based on the clinical features of VL in medi-
cal records issued by government hospitals in the study region. Typical clinical features of the
cases included fever with rigors and chills and significant splenomegaly. Cases were tested with
the rk39 leishmanin antigen by nitrocellulose dipstick tests (InBios International, Seattle,
USA). The control subjects were free of any relevant infectious disease. Pregnant women, cases
with other infections, healthy controls with a family history of VL and relatives of cases were
excluded from the study. About 5.0 mls of full venous blood were collected from study subjects
for serological and genetic studies. The samples were immediately transported to the lab and
the serum samples were separated from whole blood and stored in the same type of tubes at
-20°C until further use.
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DNA isolation and FCN2 genotyping
Genomic DNA was extracted from peripheral blood leukocytes using the protocol described
previously [27]. The reference genomic sequence was retrieved from the Ensembl database
(www.ensembl.org). The five FCN2 variants studied were PCR amplified from two genomic re-
gions. The three promoter variants -986A>G, -602G>A and -4A>G were amplified by the
primer pairs PromF-5'-ATTGAAGGAAAATCCGATGGG-3' and PromR-5'-GAAGCCACC
AATCACGAAG-3', and the two exon-8 variants +6359 C>T and +6424 G>T were amplified
using the primer pairs Exon8F-5'-CCAGCTCCCATGTCTAAAGG-3' and Exon8R-5'-
TTACAAACCGTAGGGCCAAG-3'. Primers were designed by Primer-BLAST (http://www.
ncbi.nlm.nih.gov/tools/primer-blast) and synthesized commercially (Eurofins, Bangalore,
India). The target regions were amplified using an Emerald PCR master mix (TaKaRa, Shiga,
Japan) and reactions were carried out in the ABI GeneAmp PCR system 9700. The thermal cy-
cling parameters for both amplicons were: initial denaturation at 95°C for 5 minutes, followed
by 35 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 30 seconds and elonga-
tion at 72°C for 1 minute. PCR products were purified using Exo-SAP-IT (USB-Affymetrix,
Santa Clara, USA) and 1.0 μl of the products were directly used as templates for sequencing
using the BigDye terminator (v.3.1) cycle sequencing kit (Applied Biosystems, Texas, USA) on
an ABI 3730XL DNA Analyzer. Variations were identified by assembling DNA sequences with
the reference sequence using AutoAssembler software (Applied Biosystems, Texas, USA) and
were reconfirmed visually from their electropherograms.
Ficolin-2 serological assay
Ficolin-2 levels were measured in the sera of VL cases (n = 166) and healthy controls (n = 85)
using the human Ficolin-2 ELISA kit following manufacturer’s instructions (Hycult Biotech,
Uden, The Netherlands). The detection limit of the assay was 16 ng/mL.
Statistical analysis
Data were analyzed using the STATA software (Intercooled STATA, STATA Corp., College
Station, TX, USA) and the level of significance was set to a P value of<0.05. Genotype or hap-
lotype frequencies were calculated by simple gene counting and by expectation-maximum
(EM) algorithm and the deviations from Hardy-Weinberg equilibrium were tested using the
random-permutation procedure as implemented in the Arlequin v.3.5.1.2 software (http://lgb.
unige.ch/arlequin). The linkage disequilibrium (LD) analysis was performed using Haploview
v.3.2 (http://broadinstitute.org/haploview). Multivariate analysis was performed after adjust-
ment with the confounding factors such as age, ethnicity and gender using the STATA soft-
ware. In all comparisons, P values<0.05 were considered significant. Kruskal-Wallis or
Wilcoxon-Mann-Whitney rank sum tests were applied wherever appropriate to analyze the
correlation of serum ficolin-2 levels with FCN2 variants and haplotypes by using the Kaleida-
graph software (www.synergy.com).
Results
Association of FCN2 variants with the risk of VL
The genotype and allele frequencies for the variants -986G>A, -602A>G, -4A>G and +-
6359C>T) in VL cases and controls were in Hardy-Weinberg equilibrium (P>0.05). This did
not apply to the variant +6424G>T in VL cases. This variant was excluded from further analy-
ses. The LD patterns of the FCN2 variants are given in Fig 1. The LD plot indicates that the pro-
moter variants -986G>A, -4A>G and the exon 8 variant +6359C>T were in strong LD with
Ficolin-2 and FCN2 Variants and Visceral Leishmaniasis
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each other both in cases and controls. The variant -602A>G was in LD with +6359C>T only
in controls. Significant differences were observed both in genotype and allele distributions be-
tween cases and controls for the non-synonymous variant +6359C>T (p.Thr236Met). The ho-
mozygous genotype +6359TT occurred more frequently among VL cases compared to controls
after adjusting for age, sex and ethnicity (OR = 2.2, 95%CI = 1.23–7.25, P = 0.008), indicating
that this variant was associated with an increased risk for L. donovani infection (Table 1). We
observed a similar effect of the +6359T variant, when different genetic models are employed
[Allelic: OR = 1.4, 95%CI = 1.02–1.94, P = 0.03; Recessive: OR = 2.2, 95%CI = 1.23–7.25,
P = 0.008] (Table 1). The different genetic models indicate that the +6359Tminor allele in-
creases the susceptibility of L. donovani infection. The other investigated FCN2 variants were
not significantly associated with VL.
The distribution of reconstructed FCN2 haplotypes including variants -986G>A,
-602A>G, -4A>G and +6359C>T are summarized in Table 2. Fifteen secretor haplotypes
were observed. The four haplotypes FCN2GGAC, AGGT, AAAC and GGAT occurred at
frequencies >10%. The reconstructed haplotype FCN2AAAC was found more frequently in
healthy controls compared to VL cases (OR = 0.59, 95%CI = 0.37–0.94, P = 0.023).
Fig 1. Linkage disequilibrium (LD) pattern of SNPs studied. (A): LD pattern of FCN2 variants in visceral leishmaniasis cases and (B): LD pattern of FCN2
variants in healthy controls. Numbers indicate the D’ value expressed as percentile. Open squares indicate the high degree of LD (LD coefficient D’ = 1)
between pairs of variants. The red squares indicate pairs in strong LD with LOD scores.
doi:10.1371/journal.pone.0125940.g001
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Ficolin-2 serum levels and risk of VL
Ficolin-2 serum levels were significantly higher in VL cases (mean 2.77 μg/ml) compared to
healthy controls (mean 1.94 μg/ml) (adjusted P<0.0001 for age, sex and ethnicity; Fig 2). Fico-
lin-2 levels are significantly distributed across different +6359 genotypes in controls (P = 0.03;
Fig 3). Serum ficolin-2 levels in cases with the reconstructed FCN2AAAC haplotypes were sig-
nificantly higher than those measured in individuals of the control group (P = 0.01; Fig 4).
Table 1. Distribution of FCN2 genotypes and alleles among visceral leishmaniasis cases and healthy controls.
rs17549193 (+6359C>T) (p.T236M) VL Cases n = 204 (%) Controls n = 223 (%) OR (95% CI) P# value
Genotype
CC 110 (53.9) 134 (60.1) 1 Reference
CT 72 (35.2) 80 (35.8) NA NS
TT 22 (10.7) 9 (4.1) 2.2 (1.23–7.25) 0.008
Allele
C 292 (71.5) 348 (78) 1 Reference
T 116 (28.5) 98 (22) 1.4 (1.02–1.94) 0.03
Dominant
CC 110 (53.9) 134 (60.1) 1 Reference
CT+TT 94 (46.1) 89 (39.9) NA NS
Recessive
CC+CT 182 (89.3) 214 (95.9) 1 Reference
TT 22 (10.7) 9 (4.1) 2.2 (1.23–7.25) 0.008
Note: CI, confidence interval; OR, odds ratio; NS, not significant; NA, not applicable. Percentage may not add up to 100 due to rounding errors
# Adjusted P values for age, gender and ethnicity
doi:10.1371/journal.pone.0125940.t001
Table 2. Association of functional FCN2 haplotypes and visceral leishmaniasis.
FCN2 Haplotypes (-986/-602/ -4/+6359) VL Cases n = 408(%) Controls n = 446(%) OR (95% CI) P# value
GGAC 225 (55.1) 236 (52.9) NA NS
AGGT 54 (13.2) 53 (11.8) NA NS
AAAC 36 (8.8) 62 (13.9) 0.59 (0.37–0.94) 0.023
GGAT 24 (5.8) 20 (4.4) NA NS
AAAT 16 (3.9) 12 (2.6) NA NS
AGAC 14 (3.4) 24 (5.3) NA NS
AGGC 9 (2.2) 13 (2.9) NA NS
AAGT 8 (1.9) 0 NA NA
AGAT 8 (1.9) 0 NA NA
GAAC 7 (1.7) 10 (2.2) NA NS
GGGT 4 (0.9) 12 (2.6) NA NA
GAAT 2 (0.5) 0 NA NA
AAGC 1 (0.2) 0 NA NA
GGGC 0 3 (0.6) NA NA
GAGT 0 1 (0.2) NA NA
Note: CI, confidence interval; OR, odds ratio; NS, not significant; NA, not applicable. Percentage may not add up to 100 due to rounding errors
#Adjusted P values for age, gender and ethnicity
doi:10.1371/journal.pone.0125940.t002
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Discussion
Visceral leishmaniasis develops when L. donovani parasites are successfully inoculated and sur-
vive the first-line attack of innate immune components such as phagocytes and the comple-
ment system. Indeed, these innate immune components play a major role both in the control
and establishment of L. donovani infections [28]. Complement components including lectins
are the primary molecules of the innate immune system to encounter inoculated metacyclic
promastigotes. The early activation of the complement system during pathogen invasion oc-
curs predominantly by the lectin pathway, as it is independent of a specific antibody response.
Moreover, it prompts the activation of the alternative pathway [29]. The lectin pathway protein
MBL induces opsonophagocytosis by depositing C3b on the surface of Leishmania which is
crucial for parasite survival and multiplication [13,14]. We assume that, as ficolins are func-
tionally similar to MBL, they equally influence the outcome of VL. No study so far, however,
Fig 2. Distribution of ficolin-2 serum levels in visceral leishmaniasis cases and healthy controls. Box-plots illustrate medians with 25 and 75
percentiles with whiskers to 10 and 90 percentiles. *P values were calculated by multivariate analysis adjusted for age, gender and ethnicity. Numbers in
parenthesis represent the number of samples.
doi:10.1371/journal.pone.0125940.g002
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has focused on the role of ficolin-2 in VL. We studied the contribution of ficolin-2 serum levels
and of FCN2 functional variants in VL.
The structural variant +6359C>T (p.T236M) in the fibrinogen-like domain of the FCN2
gene confers relative susceptibility to VL. The finding remains consistent in recessive and allelic
genetic models. The computational prediction revealed that the T236M substitution has a
major impact on the physiochemical property of ficolin-2 [30]. In addition, the +6359T allele
was found associated with higher ficolin-2 serum levels [31] and the observation was recon-
firmed in a cohort of neonates [32]. We also observed a similar effect of the +6359T allele in
controls, but not in cases. Our results inferred that ficolin-2 serum levels were modulated sig-
nificantly by the infection in VL cases rather than by FCN2 variants. Moreover, the ficolin-2
protein with T236M substitution had a markedly decreased binding capacity to acetylated aga-
rose beads. Therefore, this structural variant is believed to alter the binding properties of the
protein to recognize invading pathogens [24,33,34]. These reports indicate that individuals
with higher ficolin-2 serum levels and altered binding capacities might favor L. donovani
Fig 3. Distribution of ficolin-2 serum levels with +6359C>T variant in controls. Box-plots illustrate medians with 25 and 75 percentiles with whiskers to
10 and 90 percentiles. Ficolin-2 serum levels were measured and separated based on different genotypes of FCN2 variant +6359C>T. P = 0.03 illustrated in
the figure is calculated by Kruskal-Wallis rank sum test.
doi:10.1371/journal.pone.0125940.g003
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invasion into macrophages and the development of VL. Previous studies have also reported
that +6359C>T in the FCN2 gene is a risk factor for staphylococcal peritonitis in continuous
ambulatory peritoneal dialysis cases [35] and for bloodstream infections in kidney transplant
recipients [36].
In FCN2 gene-association studies, haplotype analyses should be taken into account as they
may influence disease susceptibility [37]. Our FCN2 haplotypes revealed that the FCN2AAAC
haplotype frequency was higher among controls than in VL cases, indicating that individuals
with this haplotype had a diminished probability to develop VL. The FCN2AAAC haplotype
harbors the +6359Cmajor allele, which accounts for reduced ficolin-2 levels [31,32]. In light of
Fig 4. Distribution of ficolin-2 serum levels with FCN2*AAAC in VL cases and control. Box-plots illustrate medians with 25 and 75 percentiles with
whiskers to 10 and 90 percentiles. P = 0.01 illustrated in the figure is calculated byWilcoxon-Mann-Whitney rank sum test.
doi:10.1371/journal.pone.0125940.g004
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these observations, it is evident that the FCN2 genetic factors that contribute to low ficolin-2
level decrease the risk of VL. FCN2 promoter haplotypes did not show any differences among
groups, suggesting the relative contribution of the +6359C>T genotype in Indian VL.
Ficolin-2 serum levels were elevated in VL cases compared to controls, indicating that fico-
lin-2 is a susceptibility factor. The result is in accordance with a study published previously
[15]. Corresponding results were also observed in infections withMycobacterium spp., where
higher MBL serum levels increased the risk of infection [38–40]. The proposed mechanism
may be that intracellular parasites abuse C3 opsonization and enhance opsonaophagocytosis
by monocytes/macrophages to avoid complement attacks. Any increase in the MBL and ficolin
levels in turn may enhance complement activation and, thus, the probability of parasitization
by depositing C3b on parasite surfaces [41]. Our observation supports this notion as cases with
VL had higher ficolin-2 levels than uninfected controls. Nevertheless, discordant results were
reported for ficolin-2 in tuberculosis and Chagas disease, where cases presented lower ficolin-2
plasma levels than did controls [22,42]. No clear mechanism is proposed to address the conflic-
tive observations of functionally similar proteins in intracellular habitant infections. In addi-
tion, the recognition and interaction of mannose binding lectin (MBL) with Leishmania
parasites are well established [13,14] and ficolins were shown to be functional analogous to
MBL [16]. However, a limitation of our study is that there is a lack of data showing the interac-
tion of ficolin-2 with L. donovani. Nevertheless, our earlier study demonstrated the genetic as-
sociation of FCN2 polymorphism with cutaneous leishmaniasis in Syrian population [17].
In conclusion, our results show that the FCN2 +6359C>T variant is associated with in-
creased susceptibility to VL and that the FCN2AAAC haplotype is associated with relative pro-
tection. Higher serum ficolin-2 levels were observed in cases with VL than among controls.
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